Arama Sonuçları - Salim Laghouati

  • Gösterilen 1 - 4 sonuçlar arası kayıtlar. 4
Sonuçları Daraltın
  1. 1
    378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma

    378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma Yazar: Capucine Baldini, Francois-Xavier Danlos, Aurélien Marabelle, Jean-Charles Soria, Christophe Massard, Lydie Cassard, Julien Adam, David Planchard, Andreea Varga, Gérard Zalcman, Nathalie Chaput-Gras, Matthieu Texier, Severine Mouraud, Bastien Job, Diane Letourneur, Delphine Bredel, Salim Laghouati, Nathalie Droin, Aurelien Parpaleix, Audrey Rabeau

    Baskı/Yayın Bilgisi 2021-11-01
    Makale
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

    Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized tri... Yazar: Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, Pierre Vera, Elena Ilies, Slimane Zerdoud, Jérôme Sarini, Mohamad Zalzali, Luigi La Manna, Olivier Schneegans, Antony Kelly, Philppe Kaufmann, Patrice Rodien, Laurent Brunaud, Solange Grunenwald, Elie Housseau, Salim Laghouati, Nathalie Bouvet, Elodie Lecerf, Julien Hadoux, Livia Lamartina, Martin Schlumberger, Isabelle Borget

    Baskı/Yayın Bilgisi 2023-07-01
    Tam Metin Erişim
    Makale
    Favorilerime ekle
    Kaydedildi:
  3. 3
    ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

    ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial Yazar: Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, Pierre Vera, Elena Ilies, Slimane Zerdoud, Jérôme Sarini, Mohamad Zalzali, Luigi La Manna, Olivier Schneegans, Antony Kelly, Philppe Kauffmann, Patrice Rodien, Laurent Brunaud, Solange Grunenwald, Elie Housseau, Salim Laghouati, Nathalie Bouvet, Elodie Lecerf, Julien Hadoux, Livia Lamartina, Martin Schlumberger, Isabelle Borget

    Baskı/Yayın Bilgisi 2023-04-01
    Tam Metin Erişim
    Makale
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

    Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers Yazar: Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle

    Baskı/Yayın Bilgisi 2022-07-01
    Tam Metin Erişim
    Makale
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: